DMK Pharmaceuticals Corporation

DMKPQOTCHealthcare

$0.00

+$0.00(+0.00%)

Market Cap$1010

P/E Ratio—

52W High$0.001

52W Low$0.00001

Avg Volume3K

Open$0.00

Beta0.79

Free Cash Flow Financials Revenue

DMK Pharmaceuticals Corporation (DMKPQ) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

DMKPQ · free cash flow · updated Jun 8, 2026

Core FCF metrics

DMKPQ · FCF · TTM · margin & CAGR

Free cash flow was −$26.6M for FY2022 (fiscal year ending 2022-12-31), up 31.9% year-over-year The FCF margin was -558.9%.

FY2022 Free Cash Flow−$26.6M▲ +31.9% YoY

Trailing 12M (TTM)−$9.5Mtrailing 4 quarters sum

FCF Margin-558.9%−$26.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

DMKPQ · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$25.9M(1M)−$26.6M▲ +31.9%-558.9%

FY2021−$37.8M(1M)−$39.0M▼ 80.6%—

FY2020−$20.9M(1M)−$21.6M▲ +5.1%-778.0%

FY2019−$19.9M(3M)−$22.8M▲ +37.1%-102.9%

FY2018−$32.7M(4M)−$36.2M▼ 110.2%-239.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

DMKPQ · P/FCF · FCF yield · FCF per share

DMK Pharmaceuticals Corporation (DMKPQ) reported negative free cash flow of −$0.03B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

DMKPQ · cash flow statement · operating / investing / financing

For FY2022, DMK Pharmaceuticals Corporation generated −$25.9M in operating cash flow and spent 1M in capital expenditures, yielding −$26.6M in free cash flow.

Operating Activities

−$25.9M

Cash from core business operations

2022-12-31

Investing Activities

+$3.5M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$0.3M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$25.9M) − |CapEx| (1M) = FCF (−$26.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

DMKPQ vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

DMK Pharmaceuticals CorporationYOU

DMKPQ

−$26.6M+31.9%-558.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

DMK Pharmaceuticals Corporation (DMKPQ) reported free cash flow of −$26.6M for FY2022 (fiscal year ending 2022-12-31), up 31.9% year-over-year. The FCF margin was -558.9%.

DMK Pharmaceuticals Corporation has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

DMKPQ free cash flow · 8 questions

DMK Pharmaceuticals Corporation free cash flow was −$26.6M for FY2022, up 31.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$9.5M.

DMKPQ free cash flowDMKPQ FCFDMKPQ FCF 2022DMKPQ free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · DMK Pharmaceuticals Corporation · DMK Pharmaceuticals Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026